StimCardio’s $30M Series A Puts Post-Ablation AF Care on the Wrist
LA medtech StimCardio closed an oversubscribed $30M Series A for Rhyvive, a wrist-worn therapy aimed at cutting AF recurrence after ablation.

Los Angeles just booked another capital-heavy medtech Series A — and it is not a consumer app story. StimCardio, a clinical-stage medical device company based in LA, said on Oct. 29, 2026 that it closed an oversubscribed $30 million Series A to push its investigational wrist-worn atrial fibrillation therapy through a pivotal trial and toward FDA De Novo preparation, according to the company’s announcement and coverage from MobiHealthNews.
For LA founders building hardware that touches patients, the round is a useful case study: who leads clinical device rounds, what the money is actually for, and how carefully you have to talk about efficacy when the product is still investigational.
What StimCardio raised — and who wrote the check
The Series A was led by John Slump’s family office, Metis MedTech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors. StimCardio says the financing is expected to fund the company through its planned NeuroPulse 2 pivotal multicenter study and preparation for a De Novo submission to the U.S. Food and Drug Administration.
That capital stack matters. Metis is not a generalist consumer fund; Slump’s platform emphasizes cardiovascular device experience, and the company names him as a StimCardio board member. Catalyst Health Ventures similarly frames itself around early bets on technologies that can change care. Corporate strategic investors in a Series A often signal that incumbents want a window into the category — useful distribution or partnership optionality later, but also a reminder that medtech fundraising is a different sport than raising for a B2B SaaS dashboard.
The product: investigational, wrist-worn, post-ablation
StimCardio’s lead investigational product is Rhyvive, described as a wrist-worn therapeutic wearable designed to deliver personalized, non-invasive median nerve stimulation (MNS) through a closed-loop system that integrates physiological sensing and neuromodulation. It is positioned as an adjunct to catheter ablation — meant to extend treatment beyond the procedure room into the patient’s home, with the goal of reducing recurrent atrial arrhythmias such as AF.
CAUTION: Rhyvive is an investigational device. United States law limits it to investigational use. Nothing in this article should be read as a claim that the device is cleared, approved or proven to work in commercial practice.
The clinical problem StimCardio is aiming at is large and stubborn. The company cites a 2025 Journal of the American College of Cardiology analysis of Global Burden of Disease data putting roughly 59 million people worldwide living with atrial fibrillation. Catheter ablation is an established rhythm-control option for selected patients under current guidelines, yet the company notes that roughly 30% to 40% of patients still experience recurrent AF after an initial ablation — even as ablation technology advances.
What NeuroPulse 1 showed — and what NeuroPulse 2 must prove
The financing follows StimCardio’s NeuroPulse 1 pilot study, presented as a late-breaking clinical trial at HRX Live 2026 and published peer-reviewed in Heart Rhythm. Per the company, the randomized, double-blind, sham-controlled study demonstrated a statistically significant reduction in recurrent atrial arrhythmia events post-ablation with active MNS stimulation compared with sham.
That is encouraging early evidence — and it is still only a pilot. NeuroPulse 2 is described as a major multicenter pivotal trial designed to evaluate whether adding wearable neuromodulation to catheter ablation improves clinical outcomes compared with ablation alone. For founders, the sequence is the lesson: raise enough to fund the study that regulators and payers will actually care about, then budget for the regulatory package (here, De Novo prep) in the same runway narrative.
Lessons for LA hardware and clinical founders
- Name the regulatory path in the raise. “Pivotal + De Novo prep” is a clearer use of funds than “grow the product.” Investors who understand cardiac devices expect that language.
- Lead with clinical evidence you can cite. StimCardio timed the Series A after a late-breaking presentation and a peer-reviewed publication — not before any public data.
- Stay disciplined on claims. The company’s own materials carry an investigational-use caution. Consumer-style marketing language will get you in trouble in medtech; precision is a feature.
- Match capital to timeline. Multicenter pivotal studies and FDA submissions are capital- and calendar-heavy. A $30M oversubscribed A is sized for that reality, not for a six-month growth experiment.
- Board and lead investor fit the domain. A cardiac-device operator lead plus a health-venture partner is a signal to other clinical founders in LA: domain capital still exists here if the unmet need and evidence story are sharp.
The LA medtech takeaway
StimCardio’s round is a reminder that Los Angeles can still close serious device financings when the thesis is clinical, not trendy. The company is trying to turn post-ablation AF care into something that lives on the wrist at home — but only after it earns that story through a pivotal trial and a De Novo package. For LA founders in hardware and health, copy the process discipline more than the press headline: evidence first, investigational honesty always, and raise for the study that changes the company’s destiny.
